The Federal Trade Commissioner has unanimously adopted a policy statement articulating its commitment to investigating rebates paid by drug manufacturers to pharmacy benefit managers in exchange for providing less favorable coverage to generics and biosimilars.
Approved 16 June, the statement notes that “nothing prevents drug manufacturers, PBMs, and health plans from negotiating good-faith rebates and...